SynaVir   Report issue

For profit Phase 2
Founded: San Francisco CA United States (2020)

Organization Overview

First Clinical Trial
2020
NCT04605588
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

SynaVir | Synavir Corporation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 5